Home » Newsletters » BioWorld Science

BioWorld Science

March 5, 2001

View Archived Issues

Active Biotech discusses progress during 2000

Nastech reports corporate update

Ferring initiates optimal drug protocol trial for IVF treatment

Enrollment complete in Angiotech phase II study of micellar paclitaxel for SPMS

Millennium begins phase II clinical trial of LDP-341 for treatment of multiple myeloma

FDA cancels advisory committee review of Xyrem NDA

BioMarin completes enrollment in clinical trials of MPS-I and MPS-VI treatments

First clinical study of acyline, a potent and long-acting GnRH antagonist

High contraceptive potency and excellent safety reported for microemulsion-based vaginal spermicide

Arglabin-DMA acts as an inhibitor of posttranslational processing of Ras protein

Cortez Development acquires MoliChem Medicines and changes name

Genomics collaboration between Pharmagene and Bayer expanded

Optimal dose range of pentasaccharide factor Xa inhibitor and comparison to LMWH

CPMP issues positive opinion for new NeoRecormon indication

New safety data added to Zyvox prescribing information

VENUS trial results do not support use of early nimodipine in stroke

Introgen's INGN-241 shows antitumor activity against human melanoma

GlaxoSmithKline and WHO to develop new treatment for malaria

Profile of new antiparkinsonian agent SLV-308 up to early clinical studies

Faulding to market and sell NaPro's paclitaxel in Europe

Aventis's new vector complexes useful in gene therapy of cancer

Antitumor phosphoramide compounds designed at Purdue

New GH secretagogues in development at Merck

Cephalosporins synthesized at Roche and tested for antibacterial activity

Protein kinase inhibitors and their use in the treatment of cancer presented by Agouron

Novel Nippon Kayaku compounds inhibit tumor cell proliferation

Benzazepinones and quinazolines useful for cancer, osteoporosis, etc., according to Roche

Mochida's factor Xa inhibitors endowed with in vivo anticoagulant activity

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 16, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...